Working… Menu

Effect of Higher Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01761149
Recruitment Status : Unknown
Verified January 2013 by Ru-Ping Dai, Central South University.
Recruitment status was:  Recruiting
First Posted : January 4, 2013
Last Update Posted : January 4, 2013
Information provided by (Responsible Party):
Ru-Ping Dai, Central South University

Brief Summary:
Extensive clinical studies have shown that intraoperative infusion high dose of remifentanil (0.2ug/kg/min) induced postoperative hyperalgesia. Recent experimental study however suggests that higher dose of remifentanil may attenuate postoperative hyperalgesia. Thus, the present study is designed as a "proof of principle" study and hypothesizes that higher dose of remifentanil may reduce postoperative pain in patients.

Condition or disease Intervention/treatment Phase
Nodular Goiter Drug: Remifentanil Phase 4

Detailed Description:

Remifentanil, an ultra-short acting opioid, is widely used in the patients undergoing surgery. However, extensive studies report that remifentanil,administered at 0.2ug/kg/min or 0.4ug/kg/min intraoperatively, can result in postoperative hyperalgesia and increase the consumption of analgesics when compared with low dose (0.05ug/kg/min). However, a recent experimental study shows that large dose of remifentanil can inhibit pain hypersensitivity through erasing the spinal sensitization of pain. The present study thus hypothesizes that higher dose of remifentanil (1.2ug/kg/min) may attenuate postoperative pain. The present study will compare the effect of two different dose of remifentanil (0.2ug/kg/min and 1.2ug/kg/min) on postoperative pain. Patients undergoing thyroidectomy will be recruited, and mechanical threshold will be measured in the remote region of surgical site preoperatively. The patients will be randomly divided by two groups, 0.2ug/kg/min (group I) and 1.2ug/kg/min (group II). After operation, mechanical threshold and visual analogue scale (VAS) will be measured as the indicators of postoperative pain. The consumption of morphine will also be compared between these two doses of remifentanil.

The present study may find optimized dose of opioid usage in the patients undergoing surgery to relieve the postoperative pain.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Different Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy: a Prospective, Double-blinded Randomized Control Trial
Study Start Date : December 2012
Estimated Primary Completion Date : March 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Remifentanil (Low dose)
remifentanil(Low):dose of 0.2ug/kg/min. The dose of remifentanil is widely used intraoperatively clinically;
Drug: Remifentanil
The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)

Experimental: Remifentanil (High dose)
The high dose of remifentanil is 1.2ug/kg/min. The does is sometimes used in clinical practice.
Drug: Remifentanil
The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)

Primary Outcome Measures :
  1. Changes of sensory threshold from baseline to postoperative 24hours [ Time Frame: 24 hour ]
    Quantitative sensory threshold in the remote uninjured site (here, the inner forearm) is commonly used to examine the occurrence of postoperative hyperalgesia. The present study will examine the mechanical threshold in two different doses of remifentanil to determine whether high dose of remifentanil induces hyperalgesia

Secondary Outcome Measures :
  1. visual analogue score (VAS) [ Time Frame: 24 hours ]
    VAS is widely used to assess postoperative pain. It will be divided as 10 points. Zero refers to no pain and ten refers to extremely pain. Based on this way, we can know the difference of postoperative pain in these two different groups.

Other Outcome Measures:
  1. consumption of morphine postoperatively [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ASA Grade I or II
  • Age 18-60 years old
  • BMI<35,

Exclusion Criteria:

  • do not consent,
  • Chronic pain,
  • used pain killer,
  • undergoing operation previously
  • diabetes or the other diseases affecting the sensory.
  • difficult intubation;
  • unexpected surgical complication such as bleeding;
  • psychiatric disorders;
  • drug or alchohol abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01761149

Layout table for location contacts
Contact: Ru-Ping Dai, MD, PhD 86-731-8529 ext 5970

Layout table for location information
China, Hunan
Department of Anesthesiology, The Second Xiangya Hospital Recruiting
Changsha, Hunan, China, 410011
Contact: Yan-Ling Zhang, MD    86-731-8529 ext 5970   
Sponsors and Collaborators
Central South University
Layout table for investigator information
Principal Investigator: Ru-Ping Dai, MD Central South University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ru-Ping Dai, Associate Professor, MD, PhD, Central South University Identifier: NCT01761149    
Other Study ID Numbers: XYEYYCT2013001
First Posted: January 4, 2013    Key Record Dates
Last Update Posted: January 4, 2013
Last Verified: January 2013
Keywords provided by Ru-Ping Dai, Central South University:
visual analogue score
Additional relevant MeSH terms:
Layout table for MeSH terms
Goiter, Nodular
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Neurologic Manifestations
Thyroid Diseases
Endocrine System Diseases
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents